Pharmaceutics and Drug Safety

Clinical Trials and Regulatory Affairs in Drug Development

Clinical trials and regulatory affairs are fundamental components in the successful development and approval of pharmaceutical products, ensuring that drugs are safe, effective, and of high quality before reaching the market. This session focuses on the comprehensive processes involved in clinical research, including trial design, patient recruitment, data management, and ethical considerations. With increasing complexity in drug development, especially for biologics, personalized therapies, and rare diseases, there is a growing need for innovative clinical trial designs such as adaptive trials, decentralized trials, and real-world evidence-based studies. Regulatory affairs play a crucial role in guiding pharmaceutical companies through stringent approval pathways established by global regulatory authorities, ensuring compliance with international standards and guidelines. This session will explore evolving regulatory landscapes, harmonization efforts, and the impact of global regulations on drug approval and commercialization. Key topics include Good Clinical Practice standards, informed consent, patient safety monitoring, and the role of ethics committees in safeguarding participant rights. Additionally, the session will highlight the importance of efficient regulatory strategies, documentation, and submission processes that accelerate time-to-market while maintaining safety and efficacy. Emerging technologies such as digital data capture, remote monitoring, and artificial intelligence are transforming clinical trials by improving accuracy, reducing costs, and enhancing patient engagement. Challenges such as regulatory delays, data integrity issues, and cross-border trial management will also be addressed. This session provides valuable insights into how effective clinical and regulatory practices contribute to the development of innovative therapies and ensure that patients worldwide have access to safe and reliable medicines.